Last reviewed · How we verify

NCT05956704

The Different Design of Orthokeratology

Completed NA Last updated 21 July 2023
What this trial tests

NA trial testing Orthokeratology with aspheric wide inversion zone design in the optical zone in Myopia in 90 participants. Completed in 1 June 2023.

Timeline
1 December 2020
Primary endpoint
1 June 2023
1 June 2023

Quick facts

Lead sponsorTianjin Eye Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment90
Start date1 December 2020
Primary completion1 June 2023
Estimated completion1 June 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tianjin Eye Hospital

Who can join

Adults 8 to 18, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we intend to enroll orthokeratology subjects aged 8-18 years old with binocular myopia up to and including -4.00 D. They were randomly selected to wear both orthokeratology of different designs, one with an aspheric wide inversion zone design in the optical zone and the other with a traditional spherical curved segment design, and to investigate the differences between these two lenses in terms of their effectiveness in myopia retardation, defocus, and aberration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Tianjin Eye Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05956704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing